Biography

Prof. Diane Medved Harper

University of Michigan, USA


Email: Diane.M.Harper@gmail.com


Qualifications

1995 M.Ph., Biostats /Epidemiology, University of Kansas Medical School

1986 M.D., University of Kansas Medical School (KUMC)

1982 S.M., Polymers, Massachusetts Institute of Technology

1980 S.B., Chemical Engineering, Massachusetts Institute of Technology


Publications (selected)

  1. Dykens, J. A., Peterson, C. E., Holt, H. K., & Harper, D. M. (2023). Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally. Frontiers in Public Health, 11, 1067299.
  2. Eisen, M. B., Akhmanova, A., Behrens, T. E., Diedrichsen, J., Harper, D. M., Iordanova, M. D., ... & Zaidi, M. (2022). Peer review without gatekeeping. Elife, 11, e83889.
  3. Williams, C. S., Rathmell, W. K., Carethers, J. M., Harper, D. M., Lo, Y. D., Ratcliffe, P. J., & Zaidi, M. (2022). A global view of the aspiring physician-scientist. elife, 11, e79738.
  4. Gorin, S. N. S., Jimbo, M., Heizelman, R., Harmes, K. M., & Harper, D. M. (2021). The future of cancer screening after COVID‐19 may be at home.
  5. Chen, M. M., Mott, N., Clark, S. J., Harper, D. M., Shuman, A. G., Prince, M. E., & Dossett, L. A. (2021). HPV vaccination among young adults in the US. Jama, 325(16), 1673-1674.
  6. Harper, D. M., Plegue, M., Harmes, K. M., Jimbo, M., & SheinfeldGorin, S. (2020). Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45–65 years of age in the United States. Preventive medicine, 130, 105880.
  7. Harper, D. M., Nieminen, P., Donders, G., Einstein, M. H., Garcia, F., Huh, W. K., ... & Calleja, E. (2019). The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up. Gynecologic oncology, 153(3), 521-529.
  8. LaJoie, A. S., Kerr, J. C., Clover, R. D., & Harper, D. M. (2018). Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students. Papillomavirus Research, 5, 114-121.
  9. Harper, D. M., & DeMars, L. R. (2017). HPV vaccines–a review of the first decade. Gynecologic oncology, 146(1), 196-204.
  10. Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A., ... & US Preventive Services Task Force. (2016). Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Jama, 315(23), 2564-2575.
  11. Siu, A. L., Bibbins-Domingo, K., Grossman, D. C., Davidson, K. W., Epling, J. W., García, F. A., ... & US Preventive Services Task Force. (2016). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force recommendation statement. Jama, 315(13), 1372-1377.
  12. Rachel Skinner, S., Wheeler, C. M., Romanowski, B., Castellsagué, X., Lazcano‐Ponce, E., Rowena Del Rosario‐Raymundo, M., ... & VIVIANE Study Group. (2016). Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. International journal of cancer, 138(10), 2428-2438.
  13. Skinner, S. R., Apter, D., De Carvalho, N., Harper, D. M., Konno, R., Paavonen, J., ... & Struyf, F. (2016). Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert review of vaccines, 15(3), 367-387.
  14. Harper DM, Verdenius I, Harris GD, Barnett AL, Rosemergey B, Arey AM, Wall J, Malnar GJ. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Preventive Medicine. 2014 61: 20–25.
  15. Harper DM, Irons BB, Alexander NM, Comes JC, Smith MS, et al. (2014) Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. PLoS ONE 2014 Feb 14:9(2): e88493. doi:10.1371/journal.pone.0088493
  16. Harper DM, Groner JA. Positive High-Risk HPV Test with Negative Cytology--A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):10-1.
  17. Groner JA, Harris GD, Harper DM. Reduction in HPV prevalence--no evidence to support HPV vaccination reduces HPV prevalence. Journal of Infectious Diseases. 2014 Apr 15;209(8):1302-4.
  18. Harper DM. Conclusions about HPV4 efficacy based on alternate dosing schedules and less than three dose immunogenicity is inappropriate Journal of Infectious Diseases 2014; Feb 5. doi: 10.1093/infdis/jiu072
  19. Sandri KJ, Verdenius I, Bartley MJ, Else BM, Paynter CA, Rosemergey BE, Harris GD, Malnar GJ, Harper SM, Griffith RS, Bonham AJ, Harper DM. Urban and rural safety net health care system clinics: no disparity in HPV4 vaccine completion rates. PLoS One. 2014 May 9;9(5):e96277.
  20. Else BM, Bartley MJ, Arey AM, Barnett AL, Rosemergey B, Paynter CA, Verdenius I, Harris GD, Harper SM, Groner AJ, Malnar GJ, Wall J, Bonham AJ, Harper DM. In a Safety Net Population HPV4 Vaccine Adherence Worsens as BMI Increases. PLoS ONE. 2014 Jul 30;9(7): e103172. doi:10.1371/journal.pone.0103172
  21. Harper DM, Alexander NM, Ahern DA, Comes JC, Smith MS, Heutinck MA, Handley SM. Women have a preference for their male partner to be HPV vaccinated. PLoS One. 2014 May 14;9(5):e97119.
  22. Alexander NM, Harper DM, Comes JC, Smith MS, Heutinck MA, Handley SM, Ahern DA. Intent to continue cervical cancer screening after HPV vaccination. PLoS One. 2014 Jun 10;9(6):e98665.
  23. Harper DM, Demars LR. Primary Strategies for HPV Infection and Cervical Cancer Prevention. Clin Obstet Gynecol. 2014 Jun;57(2):256-278.
  24. Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmeron J, Lehtinen M, Del Rosario-Raymundo M, Paavonen J, Teixeira J, Germar M, Peters K, Skinner R, Limson G, Castellsagué X, Poppe W, Ramjattan B, Klein T, Schwarz T, Chatterjee A, Tjalma W, Diaz-Mitoma F, Lewis D, Harper DM, Molijn A, van Doorn L, David MP, and Dubin G. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against incident and persistent infection with non-vaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA: post hoc analysis from the PATRICIA randomized trial. Clinical and Vaccine Immunology. 2015 22(2):235-244.
  25. Harper DM, Wall J, Verdenius I.  Response to Philanthropic support of HPV vaccination efforts.  Prev Med. 2015 Feb 2. pii: S0091-7435(15)00034-1. doi: 10.1016/j.ypmed.2014.12.042.
  26. Apter D, Wheeler CM, Paavonen J, Castellsagué X, Garland SM, Skinner SR, Naud P, Salmerón J, Chow SN, Kitchener HC, Teixeira JC, Jaisamrarn U, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Mindel A, de Sutter P, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; Harper DM HPV PATRICIA Study Group. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial. Clin Vaccine Immunol. 2015 Apr;22(4):361-73. doi: 10.1128/CVI.00591-14. Epub 2015 Feb 4.
  27. Skinner SR, Apter D, Harper DM, De Carvalho N, , Konno R, Paavonen J, Romanowski B, Roteli-Martins C, Kandeil W, Mihalyi A, Struyf F. Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases: a review of vaccine efficacy. Expert Review of Vaccines. 2015
  28. Kreimer AR, Struyf F, Del Rosario Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David MP, Wheeler CM, Harper DM for the Costa Rica Vaccine Trial and the PATRICIA study groups. Efficacy of Fewer than Three Doses of a HPV-16/18 AS04 adjuvanted Vaccine: a Meta Analysis of Data from the Costa Rica Vaccine Trial and the PATRICIA Trial. Lancet Oncology. 2015. Lancet Oncol. 2015 Jun 9. pii: S1470-2045(15)00047-9. doi: 10.1016/S1470-2045(15)00047-9
  29. Skinner SR, Wheeler CM, Romanowski B, Castellsagué X, Lazcano-Ponce E, Del Rosario-Raymundo MR, Vallejos C, Minkina G, Da Silva DP, McNeil S, Prilepskaya V, Gogotadze I, Money D, Garland SM, Romanenko V, Harper DM, Levin MJ, Chatterjee A, Geeraerts B, Struyf F, Dubin G, Bozonnat MC, Rosillon D, Baril L,for the VIVIANE study group. Progression of HPV infection to cervical lesion or clearance in adult women: analysis of the control arm of the VIVIANE study. International Journal of Cancer. 2015
  30. Hempstead LA and Harper DM. Incorporating Osteopathic Curriculum Into a Dually Accredited Residency Program: Maintaining Osteopathic Identity Under Single Graduate Medical Education Accreditation. Family Medicine 2015
  31. Fernandez LM, Girdler RV, Wright RB, Harper DM. IIV3 reduced flu in HIV- pregnant women and infants, and in HIV+ pregnant women but not their infants. Ann Intern Med. 2015 Feb 17;162(4):JC6. doi: 10.7326/ACPJC-2015-162-4-006.
  32. Fernandez LM, Harper DM.  Screening for CIN 3 and Cervical Cancer: Primary HPV Testing: La detección de NIC 3 y el cáncer del cuello uterino: pruebas primarias VPH. Archivos Médicos de Atualización en Tracto Genital Inferior, Año VI, No. 12 Abril 2015 Section 3 pp 1-10.
  33. Pendleton E, Ruffin MT, Harper DM. No evidence in US of HPV16/18 cancer precursor reduction.  Vaccine. 2015


Profile Details

https://medicine.umich.edu/dept/family-medicine/diane-m-harper-md-mph-ms
https://scholar.google.com/citations?user=PBdVSiYAAAAJ&hl=en&oi=ao
https://orcid.org/0000-0001-7648-883X

Free SCIRP Newsletters
Copyright © 2006-2025 Scientific Research Publishing Inc. All Rights Reserved.
Top